CL2022002682A1 - Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres - Google Patents
Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceresInfo
- Publication number
- CL2022002682A1 CL2022002682A1 CL2022002682A CL2022002682A CL2022002682A1 CL 2022002682 A1 CL2022002682 A1 CL 2022002682A1 CL 2022002682 A CL2022002682 A CL 2022002682A CL 2022002682 A CL2022002682 A CL 2022002682A CL 2022002682 A1 CL2022002682 A1 CL 2022002682A1
- Authority
- CL
- Chile
- Prior art keywords
- mirdametinib
- lifirafenib
- cancers
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002682A1 true CL2022002682A1 (es) | 2023-06-16 |
Family
ID=75674969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002682A CL2022002682A1 (es) | 2020-04-03 | 2022-09-30 | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12667560B2 (enExample) |
| EP (1) | EP4125842B1 (enExample) |
| JP (2) | JP7748386B2 (enExample) |
| KR (1) | KR20230048476A (enExample) |
| CN (1) | CN116194095B (enExample) |
| AU (1) | AU2021246141A1 (enExample) |
| BR (1) | BR112022019914A2 (enExample) |
| CA (1) | CA3174223A1 (enExample) |
| CL (1) | CL2022002682A1 (enExample) |
| CO (1) | CO2022015891A2 (enExample) |
| DK (1) | DK4125842T3 (enExample) |
| ES (1) | ES2985012T3 (enExample) |
| FI (1) | FI4125842T3 (enExample) |
| HU (1) | HUE067894T2 (enExample) |
| IL (1) | IL296878A (enExample) |
| MX (1) | MX2022012351A (enExample) |
| PE (1) | PE20231211A1 (enExample) |
| PL (1) | PL4125842T3 (enExample) |
| PT (1) | PT4125842T (enExample) |
| TW (1) | TWI893097B (enExample) |
| WO (1) | WO2021202981A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4125842T3 (pl) | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| US20230293464A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| MX2024011403A (es) * | 2022-03-17 | 2024-09-23 | Springworks Therapeutics Inc | Tratamiento con mirdametinib. |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| EP4601631A4 (en) * | 2022-10-14 | 2026-04-08 | Springworks Therapeutics Inc | COMBINATION INTENDED FOR USE IN CANCER TREATMENT |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501190A (ja) | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| EP1562601A1 (en) | 2002-11-15 | 2005-08-17 | Warner-Lambert Company LLC | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| WO2006134469A1 (en) | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
| WO2007042885A2 (en) | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2016248376B2 (en) | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| WO2019113345A1 (en) | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| PL4125842T3 (pl) | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11571402B2 (en) | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| MX2024011403A (es) | 2022-03-17 | 2024-09-23 | Springworks Therapeutics Inc | Tratamiento con mirdametinib. |
| PE20242177A1 (es) | 2022-03-17 | 2024-11-07 | St Jude Childrens Res Hospital Inc | Tratamiento del glioma de bajo grado con mirdametinib |
-
2021
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 US US17/995,002 patent/US12667560B2/en active Active
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230128315A1 (en) | 2023-04-27 |
| IL296878A (en) | 2022-12-01 |
| HUE067894T2 (hu) | 2024-11-28 |
| ES2985012T3 (es) | 2024-11-04 |
| CN116194095A (zh) | 2023-05-30 |
| PL4125842T3 (pl) | 2024-10-14 |
| EP4125842A1 (en) | 2023-02-08 |
| CO2022015891A2 (es) | 2023-05-08 |
| JP2023521036A (ja) | 2023-05-23 |
| EP4125842B1 (en) | 2024-06-05 |
| TWI893097B (zh) | 2025-08-11 |
| PT4125842T (pt) | 2024-08-06 |
| US12667560B2 (en) | 2026-06-30 |
| JP7748386B2 (ja) | 2025-10-02 |
| PE20231211A1 (es) | 2023-08-17 |
| MX2022012351A (es) | 2023-03-13 |
| DK4125842T3 (da) | 2024-07-22 |
| FI4125842T3 (fi) | 2024-08-06 |
| JP2025120501A (ja) | 2025-08-15 |
| CA3174223A1 (en) | 2021-10-07 |
| KR20230048476A (ko) | 2023-04-11 |
| CN116194095B (zh) | 2024-09-13 |
| AU2021246141A1 (en) | 2022-12-01 |
| TW202207910A (zh) | 2022-03-01 |
| BR112022019914A2 (pt) | 2022-12-13 |
| WO2021202981A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2019012884A (es) | Terapia de combinacion. | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| MX2024008886A (es) | Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2. | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CO2018004206A2 (es) | Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d” | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| MX2021003842A (es) | Terapia combinada para el tratamiento del cancer. | |
| MX394367B (es) | Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos. | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| JOP20240269A1 (ar) | حلقات كبيرة من إندازول و استخدامها |